Clinicogenomic Landscape of Pancreatic Adenocarcinoma Identifies KRAS Mutant Dosage as Prognostic of Overall Survival
Clinicogenomic Landscape of Pancreatic Ductal Adenocarcinoma: The Prognostic Role of KRAS Mutation Dosage Academic Background Pancreatic ductal adenocarcinoma (PDAC), the most common histological type of pancreatic cancer, is the third leading cause of cancer-related mortality and has the lowest five-year survival rate among all cancer types. Over ...